$4.14
4.39% yesterday
Nasdaq, Nov 14, 10:19 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US75629V1044
Symbol
RXRX

Recursion Pharmaceuticals Stock price

$4.14
-1.75 29.71% 1M
-0.17 3.94% 6M
-2.62 38.76% YTD
-2.77 40.09% 1Y
-8.56 67.40% 3Y
-27.16 86.77% 5Y
-27.16 86.77% 10Y
-27.16 86.77% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.19 4.39%
ISIN
US75629V1044
Symbol
RXRX
Industry

New AI Insights on Recursion Pharmaceuticals Insights AI Insights on Recursion Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$1.6b
Net debt
positive
Cash
$659.8m
Shares outstanding
491.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
51.7 | 30.9
EV/Sales
37.0 | 22.1
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
71.4%
Return on Equity
-44.8%
ROCE
-58.1%
ROIC
-106.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$43.7m | $73.1m
EBITDA
$-646.4m | $-648.4m
EBIT
$-723.6m | $-672.1m
Net Income
$-715.5m | $-803.5m
Free Cash Flow
$-447.7m
Growth (TTM | estimate)
Revenue
-33.0% | 24.2%
EBITDA
-70.4% | -40.9%
EBIT
-83.6% | -40.3%
Net Income
-89.4% | -73.3%
Free Cash Flow
-34.7%
Margin (TTM | estimate)
Gross
-59.0%
EBITDA
-1,479.5% | -887.5%
EBIT
-1,656.2%
Net
-1,637.8% | -1,099.7%
Free Cash Flow
-1,024.7%
More
EPS
$-1.6
FCF per Share
$-0.9
Short interest
26.1%
Employees
800
Rev per Employee
$70.0k
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

7x Buy
50%
7x Hold
50%

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
50%
Hold
50%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
44 44
33% 33%
100%
- Direct Costs 69 69
64% 64%
159%
-26 -26
213% 213%
-59%
- Selling and Administrative Expenses 220 220
61% 61%
504%
- Research and Development Expense 470 470
78% 78%
1,076%
-646 -646
70% 70%
-1,479%
- Depreciation and Amortization 77 77
421% 421%
177%
EBIT (Operating Income) EBIT -724 -724
84% 84%
-1,656%
Net Profit -716 -716
89% 89%
-1,638%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Neutral
Seeking Alpha
9 days ago
Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Ben Taylor - CFO & President of Recursion UK Presentation Christopher Gibson Co-Founder, CEO & Director " Najat Khan Chief R&D Officer, Chief Commercial Officer and D...
Neutral
GlobeNewsWire
10 days ago
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended September 30, 2025.
Neutral
GlobeNewsWire
10 days ago
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Employees 800
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today